What Factors Are Escalating the Demand Across the Adeno-Associated Virus Vector-Based Gene Therapy Market?

0
0

The increasing prevalence of genetic disorders and the growing adoption of gene therapy have propelled substantial expansion in the AAV vector-based gene therapy domain. According to detailed industry evaluation, the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68% during the forecast period. AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9 serotypes remain among the most sought-after vector platforms globally due to their low immunogenicity, broad tissue tropism, and ability to deliver therapeutic genes for long-term expression. Furthermore, the rising prevalence of genetic disorders, growing focus on personalized medicine, and supportive government initiatives are broadening the adoption base across hematological malignancies, neurological disorders, cardiovascular diseases, ophthalmic diseases, and oncology.

The market is driven by advancements in gene editing technologies and increasing prevalence of genetic disorders. Key players including Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V. are actively pursuing product innovations and strategic partnerships. Among the leading players, Biogen stands out as a leader with its approved product Zolgensma for spinal muscular atrophy. Novartis is a significant competitor with its Zolgensma gene therapy for spinal muscular atrophy, the first approved treatment of its kind. In Q4 2024, the FDA approved PTC Therapeutics' Kebilidi, the first AAV gene therapy delivered directly into the brain. Do you think AAV gene therapy will eventually become the standard treatment for genetic disorders?

FAQs

What is the current market size of the AAV vector-based gene therapy market?
The market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68%.

Which segment dominates the AAV gene therapy market?
AAV9 holds the largest market share by vector serotype, while intravenous administration leads by route. Oncology represents the largest disease type segment.

Who are the key players in the AAV gene therapy market?
Key players include Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V.

#AAVGeneTherapyMarket #GeneTherapy #GeneticDisorders #PrecisionMedicine #Biotechnology

Buscar
Categorías
Read More
Lançamentos & Anúncios
Graphite Recycling Market Demand Growth, Revenue Forecast and Market Insights
According to the latest report published by Data Bridge Market Research, the Graphite...
By Kunal Jagtap 2026-08-26 10:42:01 0 0
Conteúdo Técnico
Industrial Nailer & Stapler Market Regional Insights and Competitive Landscape
Examining the global Industrial Nailer & Stapler Market by region and competitive...
By Prajval Piche 2026-08-05 12:17:42 0 0
Entretenimento
Why Are Ophthalmic Viscoelastic Devices a Top Priority in Eye Surgery?
According to the latest report published by Data Bridge Market Research, the  Ophthalmic...
By Workin Dbmr 2026-09-16 05:35:00 0 0
Eventos & Convites
Solid Waste Management Market: Regional Dynamics and Future Growth Opportunities
Examining the global solid waste management market, covering regional dynamics across North...
By Prajval Piche 2026-08-29 07:34:52 0 0
Saúde & Bem Estar
Market Drivers and Segment Insights in the Germany Cellulite Treatment Industry
The Germany Cellulite Treatment Market is propelled by significant drivers including rising...
By Anuj Mrfr 2026-10-01 05:01:50 0 0